A Step Ahead in Secondary Prevention of Cardiovascular Risk. Consensus Document on Clinical Use of the Polypill;Un paso más allá en la prevención secundaria del riesgo cardiovascular. Documento de consenso del uso clínico del policomprimido

Revista Espanola de Cardiologia

Volumn 69, Issue 6, 2016, Pages 547-550

  González Juanatey, José Ramón ^a   Mostaza, José María ^b   Lobos, José María ^c   Abarca, Benjamín ^d   Llisterri, José Luis ^e  

^a Sociedad Espanola de Cardiologia   (Spain)

^b Lôpez Sociedad Espanola de Medicina Intensiva   (Spain)

^c Grupo de Seguridad del Paciente de la Sociedad Española de Medicina de Familia y Comunitaria semFYC   (Spain)

^d Sociedad Española de Médicos Generales Y de Familia SEMG   (Spain)

^e Fundación Sociedad Española de Médicos de Atención Primaria   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR RISK; CONSENSUS; PILL; POLYPHARMACY; POLYPILL; REVIEW; SECONDARY PREVENTION; CARDIOVASCULAR DISEASES; CONSENSUS DEVELOPMENT; DRUG COMBINATION; EUROPE; HUMAN; MEDICATION COMPLIANCE; PATIENT SELECTION; PRACTICE GUIDELINE; SPAIN;

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG COMBINATION; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; RAMIPRIL;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ASPIRIN; ATORVASTATIN CALCIUM; CARDIOVASCULAR DISEASES; DRUG COMBINATIONS; EUROPE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MEDICATION ADHERENCE; PATIENT SELECTION; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; RAMIPRIL; SECONDARY PREVENTION; SPAIN;

EID: 85016924858     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1016/j.recesp.2016.02.009     Document Type: Article

References (19)

1. J. López-Sendón, J.R. González-Juanatey, F. Pinto, J. Cuenca Castillo, L. Badimón, R. Dalmau, and et al. Indicadores de calidad en cardiología. Principales indicadores para medir la calidad de los resultados (indicadores de resultados) y parámetros de calidad relacionados con mejores resultados en la práctica clínica (indicadores de práctica asistencial). INCARDIO (Indicadores de Calidad en Unidades Asistenciales del Área del Corazón): Declaración de posicionamiento de consenso de SEC/SECTCV Rev Esp Cardiol. 68 2015 976 995.e10
2. V. Fuster Un problema alarmante en prevención secundaria, bajo cumplimiento (estilo de vida) y baja adherencia (farmacológica) Rev Esp Cardiol. 65 Supl 2 2012 10 16
3. N.K. Choudhry, J. Avorn, R.J. Glynn, E.M. Antman, S. Schneeweiss, M. Toscano, and et al. Full coverage for preventive medications after myocardial infarction N Engl J Med. 365 2011 2088 2097
4. K. Phan, Y.H. Gomez, L. Elbaz, and S.S. Daskalopoulou Statin treatment non-adherence and discontinuation: clinical implications and potential solutions Curr Pharm Des. 20 2014 6314 6324
5. L. Bryant, N. Martini, J. Chan, L. Chang, A. Marmoush, B. Robinson, and et al. Could the polypill improve adherence? The patient perspective J Prim Health Care. 5 2013 28 35
6. G. Sanz, J.M. Castellano, and V. Fuster Policomprimido: ¿quimera o realidad? Rev Esp Cardiol. 67 2014 689 692
7. González-Juanatey JR, Mostaza JM, Lobos JM, Abarca B, Llisterri JL. Nuevo enfoque terapéutico para la prevención secundaria del riesgo cardiovascular. Documento de consenso del uso clínico de la Polypill [citado 8 Ene 2016]. Disponible en: http://www.revespcardiol.org/contenidos/static/docs/Consenso%20Polypill-v4-2.pdf
8. Scottish Intercollegiate Guidelines Network. SIGN 50: A Guideline Developers' Handbook. Edinburgh: SIGN; 2001 [citado 3 May 2013]. Disponible en: http://www.sign.ac.uk/guidelines/fulltext/50/index.html
9. V. Fuster, and G. Sanz Compuestos de dosis fija en la prevención secundaria de la cardiopatía isquémica Rev Esp Cardiol. 64 Supl 2 2011 3 9
10. S. Thom, N. Poulter, J. Field, A. Patel, D. Prabhakaran, A. Stanton, and et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial JAMA. 310 2013 918 929
11. A.N. De Cates, M.R. Farr, N. Wright, M.C. Jarvis, K. Rees, S. Ebrahim, and et al. Fixed-dose combination therapy for the prevention of cardiovascular disease Cochrane Database Syst Rev. 2014 CD009868
12. V. Becerra, A. Gracia, K. Desai, S. Abogunrin, S. Brand, R. Chapman, and et al. Cost-effectiveness and public health benefit of secondary cardiovascular disease prevention from improved adherence using a polypill in the UK BMJ open. 5 2015 e007111
13. J.M. Castellano, G. Sanz, A. Fernandez Ortiz, E. Garrido, S. Bansilal, and V. Fuster A polypill strategy to improve global secondary cardiovascular prevention: from concept to reality J Am Coll Cardiol. 64 2014 613 621
14. J.M. Castellano, G. Sanz, J.L. Penalvo, S. Bansilal, A. Fernandez-Ortiz, L. Alvarez, and et al. A polypill strategy to improve adherence: results from the FOCUS project J Am Coll Cardiol. 64 2014 2071 2082
15. G. Mancia, S. Laurent, E. Agabiti-Rosei, E. Ambrosioni, M. Burnier, M.J. Caulfield, and et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document J Hypertens. 27 2009 2121 2158
16. F. Colivicchi, M. Tubaro, and M. Santini Clinical implications of switching from intensive to moderate statin therapy after acute coronary syndromes Int J Cardiol. 152 2011 56 60
17. N.J. Stone, J.G. Robinson, A.H. Lichtenstein, C.N. Bairey Merz, C.B. Blum, R.H. Eckel, and et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Circulation. 129 25 Suppl 2 2014 S1 S45
18. S. Yusuf, A. Attaran, J. Bosch, P. Joseph, E. Lonn, T. McCready, et al. Working Group on the Summit on Combination Therapy for CVD Combination pharmacotherapy to prevent cardiovascular disease: present status and challenges Eur Heart J. 35 2014 353 364
19. J.M. Castellano, J. Narula, J. Castillo, and V. Fuster Promoción de la salud cardiovascular global: estrategias, retos y oportunidades Rev Esp Cardiol. 67 2014 724 730